Milciclib
Milciclib (PHA-848125) is a potent and selective ATP-competitive inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an IC50 of 45 nM and over 3-fold selectivity against CDK1, 4, 5, and 7. This small molecule has been investigated in Phase 2 clinical trials for oncology research, with studies demonstrating its activity in both in vitro cellular assays and in vivo tumor models.
Product Specifications
CAS Number
802539-81-7
Product Name Alternative
Cyclin dependent kinase, CDK, CDK7/CyclinH, CDK5/p35, CDK4/CyclinD1, CDK2/CyclinA, Autophagy, Inhibitor, inhibit, Milciclib, Trk receptor, TrkA, Trkreceptor, PHA848125, PHA-848125, PHA 848125
Field of Research
Cell Biology, Signal Transduction
Purity
99.28% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.17 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:85 mg/mL (184.55 mM)
Smiles
CNC (=O) c1nn (C) c-2c1C (C) (C) Cc1cnc (Nc3ccc (cc3) N3CCN (C) CC3) nc-21
Molecular Formula
C25H32N8O
Molecular Weight
460.57
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
OR1075077-01 25 mg
(5S,8S) -1- (9H-Fluoren-9-yl) -5-isopropyl-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazaundecan-11-yl acetate
Sign In for Pricing
View Details OR1075077-02 50 mg
(5S,8S) -1- (9H-Fluoren-9-yl) -5-isopropyl-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazaundecan-11-yl acetate
Sign In for Pricing
View Details OR1075077-03 100 mg
(5S,8S) -1- (9H-Fluoren-9-yl) -5-isopropyl-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazaundecan-11-yl acetate
Sign In for Pricing
View Details OR1075077-04 250 mg
(5S,8S) -1- (9H-Fluoren-9-yl) -5-isopropyl-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazaundecan-11-yl acetate
Sign In for Pricing
View Details OR1075077-05 1 g
(5S,8S) -1- (9H-Fluoren-9-yl) -5-isopropyl-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazaundecan-11-yl acetate
Sign In for Pricing
View Details